From the outset, the pandemic thrust health care systems into unprecedented circumstances. Hospitals were quickly overwhelmed, with a deluge of patients requiring intensive care. Medical professionals faced shortages of personal protective equipment (PPE), ventilators, and critical supplies, forcing many to work under extreme pressure and in dangerous conditions. The rapid spread of the virus highlighted pre-existing weaknesses in health care infrastructure and disparities in access to quality care, particularly in low-income communities and developing countries.
Patients suffering from hepatic encephalopathy, a severe complication of liver disease characterized by confusion and altered consciousness due to ammonia buildup, may benefit from this combination. Clinical trials have suggested that administering L-ornithine and L-aspartate can significantly reduce ammonia levels in the blood, potentially alleviating symptoms and improving the quality of life for those affected.